140 related articles for article (PubMed ID: 23271258)
1. Current controversies in the management of biochemical failure in prostate cancer.
Bruce JY; Lang JM; McNeel DG; Liu G
Clin Adv Hematol Oncol; 2012 Nov; 10(11):716-22. PubMed ID: 23271258
[TBL] [Abstract][Full Text] [Related]
2. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
Song C; Kim YS; Hong JH; Kim CS; Ahn H
BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
[TBL] [Abstract][Full Text] [Related]
3. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
[TBL] [Abstract][Full Text] [Related]
4. Management Options for Biochemically Recurrent Prostate Cancer.
Fakhrejahani F; Madan RA; Dahut WL
Curr Treat Options Oncol; 2017 May; 18(5):26. PubMed ID: 28434181
[TBL] [Abstract][Full Text] [Related]
5. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
6. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
[TBL] [Abstract][Full Text] [Related]
7. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.
Tzou K; Tan WW; Buskirk S
Expert Rev Anticancer Ther; 2011 Jan; 11(1):125-36. PubMed ID: 21166517
[TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
Rabbani F; Perrotti M; Bastar A; Fair WR
J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen.
Kadono Y; Yaegashi H; Izumi K; Ueno S; Kitagawa Y; Mizokami A; Asahi H; Kobashi K; Koshida K; Namiki M
Anticancer Res; 2013 Mar; 33(3):1147-51. PubMed ID: 23482794
[TBL] [Abstract][Full Text] [Related]
11. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
[TBL] [Abstract][Full Text] [Related]
12. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
14. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
[TBL] [Abstract][Full Text] [Related]
15. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
16. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
17. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
18. Hormonal manipulation for rising PSA after radical prostatectomy.
Bhayani SB; Andriole GL
Semin Urol Oncol; 1999 Aug; 17(3):148-53. PubMed ID: 10462318
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
Beekman K; Morris M; Slovin S; Heller G; Wilton A; Bianco F; Scardino PT; Scher HI
Urology; 2005 May; 65(5):947-52. PubMed ID: 15882729
[TBL] [Abstract][Full Text] [Related]
20. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
